CASE REPORT

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia

Pranav Puri, BA, Kevin J. Severson, BS, Meera H. Patel, BS, Caitlin M. Brumfiel, BS, David J. DiCaudo, MD, Allison C. Rosenthal, DO, and Aaron R. Mangold, MD
Scottsdale, Arizona

Key words: acute lymphoblastic leukemia; CAR T-cell therapy; leukemia cutis.

INTRODUCTION

Recent advances in chimeric antigen receptor (CAR) T-cell therapy have demonstrated promising results for diseases ranging from acute lymphoblastic leukemia (ALL) to glioblastoma.1-2 Leukemia cutis is a rare manifestation of leukemia, in which leukemic cells infiltrate the skin; as such, there is a paucity of literature describing the effects of CAR T-cell therapy in the context of leukemia cutis. Here we present a case of B-cell lymphoblastic leukemia cutis flaring and spontaneously resolving following CAR T-cell therapy.

CASE PRESENTATION

A 21-year-old man with refractory ALL presented with numerous subcutaneous nodules along the scalp, right shoulder, and right forearm. The largest of these included a well-circumscribed, 4-cm, ovoid, raised lesion on the left lower chest wall (Fig 1, A). A skin biopsy of this chest wall lesion was performed. Histopathologic examination of the skin biopsy specimen identified a dermal infiltrate of blastic cells positive for CD19, CD20, CD22, CD79a, Pax-5, and TdT. This pattern was consistent with persistence or relapse of B-cell lymphoblastic leukemia.

Further evaluation of his B-cell lymphoblastic leukemia revealed a mass on CT sinus scan, additional extramedullary disease on PET/CT, and 60% blasts on bone marrow biopsy. He underwent apheresis for planned CAR T-cell therapy. While CAR T cells were being engineered, he received bridging radiation therapy to the sinuses and vincristine with pulse dexamethasone, which resulted in substantial improvement in his B-cell lymphoblastic leukemia cutis lesions.

He received an infusion of 2.4E8 CAR-positive viable T cells without any immediate adverse reactions. Within 3 days after infusion, he began developing numerous, slightly pruritic, indurated, red-to-purple nodules along the upper arms, chest, and back (Fig 1, B, C). Over the next 6 days, the rash progressed from the anterior upper arms (Fig 2, A) down to the upper thighs. During this time period, he also experienced intermittent fevers consistent with cytokine release syndrome.

A skin biopsy was taken from one of the right upper arm nodules. Within the superficial and deep dermis, there was a perivascular and focally nodular infiltrate composed of mononuclear cells with enlarged nuclei positive for CD19, CD20, CD22, CD79a, Pax-5, and TdT. This pattern was consistent with persistence or relapse of B-cell lymphoblastic leukemia.

Further evaluation of his B-cell lymphoblastic leukemia revealed a mass on CT sinus scan, additional extramedullary disease on PET/CT, and 60% blasts on bone marrow biopsy. He underwent apheresis for planned CAR T-cell therapy. While CAR T cells were being engineered, he received bridging radiation therapy to the sinuses and vincristine with pulse dexamethasone, which resulted in substantial improvement in his B-cell lymphoblastic leukemia cutis lesions.

He received an infusion of 2.4E8 CAR-positive viable T cells without any immediate adverse reactions. Within 3 days after infusion, he began developing numerous, slightly pruritic, indurated, red-to-purple nodules along the upper arms, chest, and back (Fig 1, B, C). Over the next 6 days, the rash progressed from the anterior upper arms (Fig 2, A) down to the upper thighs. During this time period, he also experienced intermittent fevers consistent with cytokine release syndrome.

A skin biopsy was taken from one of the right upper arm nodules. Within the superficial and deep dermis, there was a perivascular and focally nodular infiltrate composed of mononuclear cells with enlarged nuclei positive for CD19, CD20, CD10, CD79a, CD34, Pax-5, and TdT (Fig 3). Abnormal cells were negative for CD3. This was consistent with his known B-cell lymphoblastic leukemia. Treatment included diphenhydramine as needed for his pruritic symptoms and tocilizumab once for cytokine release syndrome. Three weeks following the CAR T-cell infusion, the patient’s B-cell lymphoblastic leukemia cutis resolved spontaneously without further intervention (Fig 1, D; Fig 2, B). The patient’s underlying ALL responded to CAR T-cell infusion, with 5 months of clinical remission prior to relapse.

Abbreviations used:

- ALL: acute lymphoblastic leukemia
- CAR: chimeric antigen receptor

From the Mayo Clinic.

Funding sources: None.

Correspondence to: Aaron Mangold, MD, Mayo Clinic, Department of Dermatology, 13400 E Shea Blvd, Scottsdale, AZ 85259.

E-mail: mangold.aaron@mayo.edu.

JAAD Case Reports 2021;8:64-6.
**Fig 1.** Flaring leukemia cutis with CAR T-cell therapy. **A**, Left chest wall leukemia cutis nodule prior to CAR T-cell therapy. **B**, Leukemia cutis flaring on the right aspect of the chest 5 days post-CAR T-cell initiation. **C**, Left chest wall leukemia cutis nodule flaring 5 days post-CAR T-cell initiation. **D**, Spontaneous resolution of left chest wall leukemia cutis nodules (photo taken 15 days post-CAR T-cell initiation). *CAR*, Chimeric antigen receptor.

**Fig 2.** **A**, Leukemia cutis flaring on right upper arm 5 days post-CAR T-cell initiation. **B**, Spontaneous resolution of left forearm leukemia cutis nodules (photo taken 15 days post-CAR T-cell initiation). *CAR*, Chimeric antigen receptor.
DISCUSSION

To the best of our knowledge, this is the first documented case of B-cell lymphoblastic leukemia cutis flaring and spontaneously resolving following CAR T-cell therapy in a patient with ALL. A previous phase I study of CAR T-cell therapy in high-risk acute myeloid leukemia reported a similar presentation in a patient with a previous history of leukemia cutis. This patient developed a transient skin rash 4 days after infusion. The rash resolved in 5 days without any specific management. On day 22 after infusion, the patient developed another rash with infiltration of acute myeloid leukemia blasts with subsequent disease progression. In addition, a previous case series of 5 patients documented dermatologic complications potentially associated with CAR T-cell therapy. Dermatologic complications in this series included 1 patient with Merkel cell carcinoma, 2 patients with unusual mononuclear cell dermal infiltrates, and 2 patients with transient eruptions consistent with “eruption of lymphocyte recovery.”

CAR T-cell therapy has revolutionized the treatment landscape for relapsed refractory hematologic malignancies including ALL, though little is known about its effect on leukemia cutis. Our report documents a clear case of flaring disease in the skin, which resolved spontaneously without further intervention after CAR T-cell therapy. This case suggests that disease flare may not be indicative of CAR T-cell therapy failure. In such cases, monitoring the flare with expectant management and symptomatic treatment following CAR T-cell therapy may be a reasonable approach in the short term. Additional case series are needed to determine the natural disease course of individuals with leukemia cutis undergoing CAR T-cell therapy.

Conflicts of interest

None disclosed.

REFERENCES

1. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449-459.
2. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561-2569.
3. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122-2129.
4. Rubin CB, Elenitsas R, Taylor L, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. 2016;75:1054-1057.